Here are seven articles published by Becker's Hospital Review this week, featuring a look into the efficacy of outcomes-based drug pricing contracts, one hospital's unique attempt to attract blood donors and a report on cybersecurity vulnerabilities in industrial robots, among other topics.
1. Are outcomes-based drug contracts effective? 5 thoughts
Outcomes-based drug pricing, which sets drug prices based on how much they improve patients' health, is gaining steam in the U.S. healthcare system. However, many industry stakeholders are skeptical of the methodology, which has few proven benefits.
2. Chicago blood supplier says Illinois' summer shortage is worst it's ever seen
Chicago-based LifeSource, one of the largest blood suppliers in Illinois, says this summer's blood shortage is the worst they've ever seen.
3. How Trump's efforts to lower drug prices affect the industry — 4 questions on a possible executive order
President Donald Trump and his staff are working on an executive order aimed at lowering drug prices. Michael Strazzella, Practice Group Leader of Federal Government Relations, and William Garvin, a shareholder at Buchanan, Ingersoll & Rooney, discuss the implication of efforts to lower pharmaceutical prices on the industry.
4. Why supply chain leaders should practice unlearning
Unlearning tasks or concepts can be difficult and counter-intuitive, but often important in the supply chain industry.
5. Industrial robots vulnerable to cyberattacks, report finds
A recent study found many machines used in industrial settings are vulnerable to cyberattacks.
6. RWJ University Hospital Somerset attracts blood donors with free round of golf
Individuals who donate blood at Somerville, N.J.-based Robert Wood Johnson University Hospital Somerset this summer will receive a free round of golf from the Somerset County Parks Commission.
7. Pharma, device industry gave $8B+ to physicians and hospitals in 2016
Drug and devicemakers shelled out more than $8 billion in payments to physicians and teaching hospitals last year.
More articles on supply chain:
7 things to know about drug spending composition in 5 countries
House passes FDA user fee reauthorization bill
Zimmer Biomet CEO steps down: 3 things to know